Peptides for Muscle Growth: GH Secretagogues Explained

Muscle growth past the beginner phase is a hormonal problem as much as a training problem. Testosterone, growth hormone, IGF-1, and insulin all signal to muscle tissue that growth is appropriate. The Hartman et al. study (J Clin Endocrinol Metab 2006) documented mean GH decline of roughly 14% per decade after age 25 — meaning a 45-year-old has 35-40% less circulating GH than they did at 25. Lifting harder doesn't solve the signaling problem.

Peptide protocols for muscle growth fall into two classes. Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin) raise endogenous GH pulses, which downstream raises IGF-1 and supports lean mass synthesis. Recovery peptides (BPC-157, TB-500) protect training capacity by accelerating tissue repair between sessions, allowing higher intensity and frequency.

None of these compounds replace anabolic steroids. They are subtler tools that work with your existing hormonal axis rather than overriding it. The advantage is a substantially better safety profile, less endocrine disruption, and no post-cycle therapy required. The cost is smaller effect size — expect modest gains compounded across multiple cycles, not the dramatic transformations associated with TRT or AAS protocols.

GH secretagogue stacks (CJC-1295 + ipamorelin) raise endogenous GH pulses by 2-5x in healthy adults. The Teichman et al. study (J Clin Endocrinol Metab 2006) established this with CJC-1295 monotherapy in healthy volunteers — single 1 mg dose raised 24-hour mean GH 2-10x with IGF-1 increases of 1.5-3x sustained for 7-14 days.

The combined CJC-1295 + ipamorelin stack hits two receptors simultaneously: CJC-1295 activates GHRH receptors (raising the baseline), ipamorelin activates ghrelin receptors (triggering pulse release). The combination produces stronger and cleaner GH pulses than either alone. The Sigalos and Pastuszak review (Sex Med Rev 2018) compiled practitioner data showing 1.5-2.5% body weight in additional muscle gain per 12-week cycle on top of well-programmed training.

BPC-157 plays a different role. By accelerating tissue repair between sessions, it lets you train at higher intensity or higher frequency without breaking down. The downstream effect on muscle growth comes from the additional training stimulus, not direct anabolic action. The training would not be sustainable without the recovery support.

Real-world results are modest compared to anabolic protocols. Expect 1-3% additional muscle gain per 12-week cycle. The compounding effect across 2-3 cycles per year is what makes the protocols worth the cost.

Muscle growth response to peptides varies by genotype. Three SNP clusters matter most:

• ACTN3 rs1815739 — the "speed gene" encoding alpha-actinin-3. R/R homozygotes have higher fast-twitch fiber percentages and respond more strongly to hypertrophy protocols. R/X and X/X carriers tend toward endurance phenotypes with smaller hypertrophy response.
• MSTN (myostatin) variants — myostatin levels affect baseline muscle mass and growth ceiling. Lower-expression variants predict naturally muscular phenotypes and slightly stronger response to GH secretagogues. Functional MSTN loss-of-function variants are rare but produce dramatic muscle phenotypes (the "double-muscled" cattle case).
• GHR (growth hormone receptor) exon-3 polymorphism — affects tissue sensitivity to GH. The d3 variant carriers show stronger downstream response to elevated GH, predicting larger effect from CJC-1295 + ipamorelin protocols.
• IGF-1 promoter variants — affect baseline IGF-1 production and response to GH stimulation. Predicts the magnitude of downstream effect from GH secretagogue protocols.

A pharmacogenomic report identifies whether GH secretagogues will work hard for you or barely move the needle. If your DNA shows high-MSTN expression + GHR fl/fl + ACTN3 X/X, your expected response to GH secretagogue protocols is below population mean — your effort is better spent on training optimization or considering TRT protocols (with proper medical supervision). If your DNA shows the opposite pattern (low MSTN + GHR d3 + ACTN3 R/R), expected response is above mean and the cycling protocol carries higher expected value.

CJC-1295 monotherapy (Teichman et al., J Clin Endocrinol Metab 2006). Single 1 mg subcutaneous in healthy adult volunteers raised mean 24-hour GH 2-10x with IGF-1 increases of 1.5-3x sustained over 7-14 days. The study established the twice-weekly dosing rationale that became standard practice.

CJC-1295 + ipamorelin combined (Sigalos and Pastuszak, Sex Med Rev 2018). Review of practitioner protocols and case data. Mean fat mass loss of 1.5-2.5% body weight + lean mass preservation over 12 weeks when paired with resistance training. Not a controlled trial but the cleanest practitioner dataset available.

Ipamorelin selectivity (Raun et al., Eur J Endocrinol 1998). Established ipamorelin's clean GH selectivity. Unlike older GH secretagogues, ipamorelin does not significantly elevate cortisol, prolactin, or aldosterone — meaning the muscle-growth signal comes through clean without unwanted hormone spillover.

Sermorelin in elderly trial (Vittone et al., Metabolism 1997). 18 healthy elderly adults. Sermorelin (related GHRH analog) 1 mg/day for 16 weeks raised IGF-1 by 35%, increased lean body mass, and reduced fat mass versus placebo. The clearest demonstration that endogenous GH stimulation produces body composition changes in older adults.

BPC-157 muscle regeneration (Mihalj et al., J Pharm Pharmacol 2018). Rat gastrocnemius laceration model. Faster myofiber regeneration at 14 days. Establishes the recovery-acceleration mechanism that supports higher training frequency.

Hartman et al. GH decline (J Clin Endocrinol Metab 2006). Documented mean GH decline of ~14% per decade after age 25, with corresponding IGF-1 decline. Establishes the biological rationale for GH secretagogue protocols in adults over 30.

If you're under 30 and natural training is producing gains: Skip GH secretagogues. Endogenous GH is at peak; the additional signal produces marginal benefit not worth the cost. Focus on training optimization, nutrition, and sleep.

If you're 30-45 and progress has stalled despite well-programmed training: CJC-1295 + ipamorelin is the cleanest entry point. GH decline is meaningful at this age. The 12-week cycle restores 24-hour GH output to roughly mid-20s levels.

If you're 45+ and want to preserve or rebuild lean mass: Same protocol with potentially higher value. The Hartman 2006 data shows GH decline is most pronounced in this age range. Consider adding BPC-157 for recovery support if training intensity is high.

If recovery between sessions is the bottleneck (not GH itself): Lead with BPC-157 monotherapy for 8 weeks. Add CJC-1295 + ipamorelin in cycle 2 if hypertrophy is the goal.

If you carry ACTN3 R/R + low MSTN + GHR d3: Strongest fit for GH secretagogue protocols. Expected response above population mean. Worth the cost.

If you carry ACTN3 X/X + high MSTN: Expected response below mean. GH secretagogues are not your best lever. Consider training optimization, careful nutritional periodization, or (under physician care) TRT.

If you have personal or family history of cancer: Avoid GH secretagogues. The theoretical IGF-1/cancer link is enough to warrant conservative exclusion. BPC-157 has no clear contraindication for recovery support.

If competing in WADA-compliant sport: All GH secretagogues on the prohibited list. Plan strictly out-of-competition with adequate washout windows.

Standard hypertrophy stack. CJC-1295 1 mg subcutaneous twice weekly (Monday and Thursday evenings). Ipamorelin 200-300 mcg subcutaneous pre-bed nightly. Optional add: BPC-157 250 mcg/day during high-volume training blocks for recovery support.

Cycle structure. 8-12 weeks on, 4-6 weeks off. Receptor sensitivity declines on continuous use beyond 12 weeks. Off-cycle, training adaptations continue at slower trajectory. Most users run 2-3 cycles per year.

Critical timing. Do not eat carbohydrates within 60 minutes of GH secretagogue injection. Insulin blunts the GH pulse 50-80%. Pre-bed timing for ipamorelin works because most people are 3-4 hours fasted by then. Inject 90 minutes before sleep for the deepest pulse alignment with slow-wave sleep.

Resistance training non-negotiable. These peptides amplify training adaptation. Without the training stimulus, they do nearly nothing for muscle growth — though they still affect fat mass and recovery. Plan for 3-5 resistance sessions per week minimum during cycles.

Protein target. 1.6-2.2 g/kg body weight per day. Below this, the additional GH and IGF-1 signaling has no raw material to work with. Distribute protein across 4-5 feedings to maximize per-feeding muscle protein synthesis.

Sleep is the multiplier. Most endogenous GH output happens during slow-wave sleep in the first 90 minutes of sleep. Pre-bed ipamorelin amplifies this peak. Poor sleep architecture (interrupted, late bedtime, alcohol within 2 hours) wastes the protocol.

Week 1-2. No visible muscle change. Sleep quality typically improves within 4-5 days — first sign the GH pulse is amplifying. Some users report better workout recovery in the first week.

Week 3-4. Subtle changes. Slightly fuller muscle look from elevated glycogen storage. Workout volume tolerance increases — recovery between sessions feels faster. Scale weight may bump 1-2 lb (water + glycogen + early lean mass).

Week 5-8. First real visible muscle changes. Most users report measurable improvements in arm and shoulder fullness. Strength on compound lifts often increases 5-10% during this window despite slow scale movement.

Week 9-12. Peak effect window. This is when the cleanest body composition changes show in DEXA or photos. Expect 1-3 lb of lean mass on top of well-programmed training, with simultaneous mild fat loss. The visible result is "fuller and tighter."

Week 13-16 (cycle break). Hold gains during 4-week off-cycle. Most users maintain composition if training and protein discipline continue. Some loss of the water/glycogen bump is expected (1-2 lb scale drop is normal).

Cycle 2 and beyond. Diminishing returns are real but compounding. Second cycle typically produces 60-70% of first-cycle effect. Across 3 cycles in a year, total muscle gain of 5-8 lb on top of training is realistic — well below anabolic protocols but with much better safety profile and no PCT requirement.

Carbohydrates within 60 minutes of injection. Single biggest mistake. Insulin blunts the GH pulse 50-80%. Eating dinner at 8 PM then injecting CJC-1295 + ipamorelin at 9 PM wastes most of the dose. Inject 3-4 hours after the last meal, ideally pre-bed.

Skipping the cycle break. Receptor sensitivity declines on continuous use beyond 12 weeks. Twelve weeks on becomes 14, then 16, then "permanent low-dose maintenance" with measurably weaker pulse response. The 4-week break preserves effect across the year. Cumulative annual effect on a cycled protocol exceeds continuous low-dose use.

Inadequate protein. 1.6-2.2 g/kg is the floor. Below this, the additional GH and IGF-1 signaling has no raw material to work with. The most common pattern: lifting hard, peptides on board, eating 1.0 g/kg protein, wondering why nothing changes. Track protein for the first 4 weeks until the habit is locked.

Stacking too many peptides simultaneously. CJC-1295 + ipamorelin + BPC-157 + TB-500 + AOD-9604 day one makes attribution impossible. Start with CJC-1295 + ipamorelin alone for the first cycle. Add BPC-157 in cycle 2 if recovery is the bottleneck. Add AOD-9604 only if fat-loss is the simultaneous goal.

Expecting steroid-level results. GH secretagogue stacks produce 1-3% additional muscle gain per cycle. Anabolic steroids produce 5-15% over similar windows. They're different categories. Going in expecting AAS results sets up disappointment. Going in expecting subtle compounding gains sets up satisfaction.

Buying low-quality CJC-1295 (DAC vs no-DAC confusion). CJC-1295 comes in two forms: with DAC (drug affinity complex, long half-life) and without DAC (short half-life). The standard twice-weekly dosing assumes with-DAC version. No-DAC requires daily injection. Vendors often misrepresent the form. Verify before starting protocol.

CJC-1295 + ipamorelin. Generally well-tolerated. Common (>10%): mild water retention especially first 2 weeks, occasional injection-site reactions, mild flushing immediately after injection. Less common: numbness or tingling in extremities (carpal tunnel-like, dose-related, resolves on dose reduction), elevated fasting glucose at higher doses, mild headaches.

BPC-157. No serious adverse events in 200+ animal studies. Human safety data limited to practitioner experience. Common: mild injection-site reactions, occasional headache in first week.

Monitoring. Baseline + 12-week labs: fasting glucose, HbA1c, IGF-1, CBC, CMP. Stop the protocol if IGF-1 exceeds 350 ng/mL — the practical signal of excessive GH stimulation. Some practitioners track HbA1c during extended cycles as a sensitivity check.

Contraindications. Active or history of cancer (GH and IGF-1 can theoretically accelerate tumor growth — clinical evidence is mixed but conservative practice excludes these patients). Active proliferative diabetic retinopathy. Pregnancy or active conception attempts. Significant prior history of carpal tunnel syndrome.

Cancer concern context. The theoretical link between elevated IGF-1 and cancer risk is supported by epidemiologic studies in some populations but not consistently. Patients with prior cancer history should avoid GH secretagogues unless explicitly cleared by their oncology team. The conservative path is to avoid in this population.

WADA status. CJC-1295, ipamorelin, sermorelin all explicitly prohibited under WADA Section S2 (peptide hormones). For competitive athletes, protocols must end well before competition with adequate washout. Out-of-competition use during off-season is the realistic window.